Robert Ross
President bei SURFACE ONCOLOGY, INC.
Profil
Robert W.
Ross is an Independent Director at Xilio Therapeutics, Inc. since 2022.
He is also a Director at Obsidian Therapeutics, Inc. since 2020.
Prior to his current positions, he served as the President of Surface Oncology, Inc. from 2016 to present.
Before that, he was the Senior Vice President-Clinical Development at bluebird bio, Inc. from 2015 to 2016.
Dr. Ross completed his undergraduate studies at Stanford University and pursued graduate degrees at Harvard Medical School and Columbia University College of Physicians & Surgeons.
Aktive Positionen von Robert Ross
| Unternehmen | Position | Beginn |
|---|---|---|
| SURFACE ONCOLOGY, INC. | President | - |
| XILIO THERAPEUTICS, INC. | Director/Board Member | 16.06.2022 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 03.09.2020 |
Ehemalige bekannte Positionen von Robert Ross
| Unternehmen | Position | Ende |
|---|---|---|
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01.10.2016 |
Ausbildung von Robert Ross
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Graduate Degree |
| Columbia University College of Physicians & Surgeons | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
